TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Kassem, Loay ^a   Deygas, Mathieu ^b   Fattet, Laurent ^b   Lopez, Jonathan ^b   Goulvent, Thibaut ^b   Lavergne, Emilie ^c   Chabaud, Sylvie ^c   Carrabin, Nicolas ^c   Chopin, Nicolas ^c   Bachelot, Thomas ^c   Gillet, Germain ^b   Treilleux, Isabelle ^c   Rimokh, Ruth ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b UNIVERSITÉ DE LYON   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SMAD4 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1GAMMA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; SMAD4 PROTEIN, HUMAN; TRIM33 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CELL NUCLEUS; CLINICAL FEATURE; CYTOPLASM; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OPERABLE BREAST CANCER; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL; TUMOR VOLUME; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA; CHEMISTRY; MIDDLE AGED; PATHOLOGY; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CELL NUCLEUS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SURVIVAL RATE; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN;

EID: 84930667821     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1471-y     Document Type: Article

References (35)

1. Wakefield LM, Piek E, Bottinger EP. TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2001;6(1):67-82.
2. Bierie B, Gorska AE, Stover DG, Moses HL. TGF-beta promotes cell death and suppresses lactation during the second stage of mammary involution. J Cell Physiol. 2009;219(1):57-68.
3. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res. 2005;65(6):2296-302.
4. Massague J. TGFbeta in cancer. Cell. 2008;134(2):215-30.
5. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Gene Dev. 2002;12(1):22-9.
6. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506-20.
7. Heldin CH, Moustakas A. Role of Smads in TGFbeta signaling. Cell Tissue Res. 2012;347(1):21-36.
8. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci. 2005;118(Pt 16):3573-84.
9. Massague J, Xi Q. TGF-beta control of stem cell differentiation genes. FEBS Lett. 2012;586(14):1953-8.
10. Dupont S, Inui M, Newfeld SJ. Regulation of TGF-beta signal transduction by mono- and deubiquitylation of Smads. FEBS Lett. 2012;586(14):1913-20.
11. Hesling C, Fattet L, Teyre G, Jury D, Gonzalo P, Lopez J, et al. Antagonistic regulation of EMT by TIF1gamma and Smad4 in mammary epithelial cells. EMBO Rep. 2011;12(7):665-72.
12. Fattet L, Ay AS, Bonneau B, Jallades L, Mikaelian I, Treilleux I, et al. TIF1gamma requires sumoylation to exert its repressive activity on TGFbeta signaling. J Cell Sci. 2013;126(Pt 16):3713-23.
13. Hesling C, Lopez J, Fattet L, Gonzalo P, Treilleux I, Blanchard D, et al. Tif1gamma is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Dev (Cambridge England). 2013;140(1):167-75.
14. Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, Kaniewski B, et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet. 2009;5(7):e1000575.
15. Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, et al. Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest. 2011;121(6):2361-70.
16. Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2011;108(20):8212-7.
17. Jain S, Singhal S, Francis F, Hajdu C, Wang JH, Suriawinata A, et al. Association of overexpression of TIF1gamma with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World J Gastroenterol WJG. 2011;17(35):3994-4000.
18. Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, Soares FA, et al. Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2010;21(4):734-40.
19. Panis C, Herrera AC, Victorino VJ, Aranome AM, Cecchini R. Screening of circulating TGF-beta levels and its clinicopathological significance in human breast cancer. Anticancer Res. 2013;33(2):737-42.
20. Koumoundourou D, Kassimatis T, Zolota V, Tzorakoeleftherakis E, Ravazoula P, Vassiliou V, et al. Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2, N0 tumours. Anticancer Res. 2007;27(4c):2613-20.
21. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y. Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer. 2006;94(2):239-46.
22. Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 2012;5:110.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006;100(2):229-35.
24. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz Jr AB. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surgery (Chicago, Ill: 1960). 1990;125(1):107-13.
25. Kaplan EM P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-81.
26. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34(2):187-220.
27. Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle (Georgetown Tex). 2009;8(20):3319-27.
28. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002;62(2):497-505.
29. de Kruijf EM, Dekker TJ, Hawinkels LJ, Putter H, Smit VT, Kroep JR, et al. The prognostic role of TGF-beta signaling pathway in breast cancer patients. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2013;24(2):384-90.
30. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005;102(39):13909-14.
31. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006;66(4):2202-9.
32. Andrieux G, Fattet L, Le Borgne M, Rimokh R, Théret N. Dynamic regulation of Tgf-B signaling by Tif1γ: a computational approach. PLoS One. 2012;7(3):e33761.
33. Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors (Chur, Switzerland). 2011;29(4):140-52.
34. Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761. Cancer Res. 2011;71(6):2339-49.
35. Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. FEBS Lett. 2012;586(14):1959-70.